<DOC>
	<DOCNO>NCT00488397</DOCNO>
	<brief_summary>In-vitro surveillance study tigecycline ( Tygacil ) Taiwan .</brief_summary>
	<brief_title>Tigecycline In-Vitro Surveillance Study In Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Community-Acquired Infections</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<criteria>Clinically relevant causative isolate ( duplicate ) The isolate must meet laboratory criterion `` significant pathogen '' consider `` probable causative agent '' hospital community acquire infection . Sources All body sit acceptable clinical source isolate include study ( Intraabdominal infection , tracheal secretion/bronchoalveolar lavage , blood culture , wound smear ) . However , 10 % isolate come urine culture . Within study group Only isolate define protocol include . Limited isolates source No 10 % isolates study derive urine culture . No banked store isolates . No duplicate isolate Only one isolate per patient permit . Outside study group Any isolate define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Tygacil</keyword>
	<keyword>microdilution method</keyword>
	<keyword>Tigecycline</keyword>
	<keyword>In-Vitro</keyword>
</DOC>